All Latest News
-
Adare Pharma Solutions Opens New Small-Scale Laboratory to Offer Faster and More Efficient Development Capabilities to Clients
Press Release ArchivesNew laboratory brings customizable, flexible systems to expedite formulation and process development services Provides customers more early stage development capacity Lawrenceville, NJ January 26, 2021 Adare Pharma Solutions,... Learn More
-
THOMAS H. LEE PARTNERS AND FRAZIER HEALTHCARE PARTNERS ACQUIRE ADARE
Press Release ArchivesBoston, MA and Seattle, WA - September 22, 2020 Transaction includes specialty CDMO business, including pharmaceutical technology and microbiome businesses Thomas H. Lee Partners, L.P. (“THL”) and Frazier Healthcare Partners... Learn More
-
Adare Pharmaceuticals, Inc. Acquires Orbis Biosciences
Press Release ArchivesLawrenceville, NJ, and Lenexa, KS - May 4, 2020 Kansas-based pharmaceutical technology company develops customized formulations and intellectual property Deal includes platforms that can be dosed in oral, injectable and otic (ear)... Learn More
-
Adare Pharmaceuticals and NLS Pharmaceutics collaborate to develop mazindol controlled release (CR) for the treatment of ADHD and narcolepsy
Press Release ArchivesLawrenceville, NJ & Switzerland - January 13, 2020 Adare Pharmaceuticals, Inc. (Adare) and NLS Pharmaceutics Ltd. (NLS) announced today a collaboration to develop mazindol (MZD) CR product candidates for the treatment of narcolepsy... Learn More
-
Adare acquires Egalet’s proprietary “Parvulet®” technology platform
Press Release ArchivesPrinceton, NJ & Wayne, PA - April 15, 2019 Adare Pharmaceuticals, Inc. today announced that it has entered into an agreement with Egalet Corporation (OTCQX: ZCOR), to acquire global rights of the “ParvuletTM” technology platform... Learn More
-
Primary End-Point achieved in Phase IIb Study (FLUTE™) for APT-1011
Press Release ArchivesPrinceton, New Jersey - March 12, 2019 Adare Pharmaceuticals (Adare) today announced positive results from its Phase IIb study (FLUTE™) for one of its rare disease investigational products, APT-1011 (AdvaTab® Fluticasone) for... Learn More
-
Lannett and Adare Enter Into Distribution Agreement
Press Release ArchivesPhiladelphia, PA & Princeton, New Jersey - October 22, 2018 Lannett Company, Inc. (NYSE: LCI) today announced that it has entered into an agreement with Adare Pharmaceuticals, Inc., to be the exclusive U.S. distributor of... Learn More
-
Adare Licenses Cyclobenzaprine Hydrochloride in Portugal
Press Release ArchivesPrinceton, New Jersey - October 8, 2018 Adare Pharmaceutical Technologies, the specialty CDMO business unit of Adare Pharmaceuticals, has completed a licensing and supply agreement with Bene Farmacêutica (Bene) for cyclobenzaprine... Learn More
-
Adare Pharmaceuticals announces changes to Executive Leadership Team
Press Release ArchivesPrinceton, New Jersey - May 8, 2018 Adare Pharmaceuticals, Inc., today announced changes to its Leadership Team to support the next phase of its growth strategy. Since its creation in 2015, the Company has been committed to becoming a... Learn More